Donepezil therapy in clinical practice: a randomized crossover study. - sprookjes - yvandenbroek - TriplyDB

Donepezil therapy in clinical practice: a randomized crossover study.

Donepezil therapy in clinical practice: a randomized crossover study.

http://www.wikidata.org/entity/Q33145215

about

Long-term course and effectiveness of combination therapy in Alzheimer disease Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT Systematic Review: Representativeness of Participants in RCTs of Acetylcholinesterase Inhibitors Donepezil (Aricept) for treatment of Alzheimer's disease and other dementing conditions.The developing utility of zebrafish models for cognitive enhancers research The use of medications for cognitive enhancement.Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia gravis.Anticholinesterase-induced symptoms improved by pacemaker implantation in patients with Alzheimer's disease: analysis of 6 cases.Insights and ideas garnered from marine metabolites for development of dual-function acetylcholinesterase and amyloid-β aggregation inhibitors Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.Care of older people: Mental health problems Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder.Muscarinic M(1) agonists in the treatment of Alzheimer's disease.Apolipoprotein E polymorphisms and concentration in chronic diseases and drug responses.Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment.Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.Cholinesterase inhibitor and N-methyl-D-aspartic acid receptor antagonist use in older adults with end-stage dementia: a survey of hospice medical directors.Gene identification in Alzheimer's disease.The safety and tolerability of donepezil in patients with Alzheimer's disease.Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.Donepezil in Alzheimer's disease: From conventional trials to pharmacogenetics Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study.Goal setting and attainment in Alzheimer's disease patients treated with donepezil.A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer's Disease.Neuropsychiatric pharmacogenetics: moving toward a comprehensive understanding of predicting risks and response.Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes.Pharmacologic treatment of adolescent and child schizophrenia.Cholinesterase inhibitors in Alzheimer's disease and Lewy body spectrum disorders: the emerging pharmacogenetic story.Donepezil: a review.Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study.Safety and efficacy of rivastigmine in patients with Alzheimer's disease not responding adequately to donepezil: an open-label study The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.Current therapeutic options for Alzheimer's disease Have last-observation-carried-forward analyses caused us to favour more toxic dementia therapies over less toxic alternatives? A systematic review.Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats.The effect of funding sources on donepezil randomised controlled trial outcome: a meta-analysis.Pharmacogenomics in neurology: current state and future steps.Four Decades of Research in Alzheimer's Disease (1975-2014): A Bibliometric and Scientometric Analysis.Donepezil for memory dysfunction in schizophrenia.

P2860

Q24642161-C11C3CAE-BFBD-423D-9618-F5A1E25882C3 Q26749755-FCEB3FE9-71CC-40AD-A55D-632A0FE3E96D Q26863383-7DC50D00-110F-4BFD-AB84-BAEE548523BC Q30436664-0BB7DFB3-0F4F-4329-AB10-853D98E1777E Q30457705-66AC5237-CF26-4341-BD6D-5DB469A8B211 Q32122238-746C4CA5-6474-42D8-8D25-0E802474593C Q33155451-413995AD-EEAA-4DB3-9572-7E077A6664AA Q33161551-3A8FBA32-708C-4A94-8206-B5EC190B20A5 Q33575660-5567AEA1-E798-435E-90B8-D3CAC1FA0258 Q33750604-612DBCC9-F77D-4A98-99D2-67A2691CBAB3 Q33804768-F9C84E9D-180D-4193-9F22-7F67D9B20FF3 Q33912750-F55227D2-6975-4FC6-84BF-96AF3F7AF137 Q33945438-3A6B78C8-5DBF-49C6-9F9A-F249F9FD38D5 Q34075102-19F246FC-24A6-4DA5-B5E2-63A3A3706C52 Q34093070-EF237004-A46E-4EA8-AE7D-4587298B5D6C Q34128361-2E87DC4E-567E-4B59-8BC6-01856B044F39 Q34327769-1C555510-00EA-4820-BEFB-6FCFF0980F9B Q34334170-8EE0B88E-39A4-4D0B-9B48-6D0E9EEF1FCA Q34355252-DA0699F0-A620-4722-BABA-5C2B260C5770 Q34552035-6EFF6F18-74E0-417F-BD38-4ADD21D508EF Q34648742-A07771C7-3CC1-4592-ADD6-CB88C594A681 Q34965949-2AC64A6B-219F-4CF2-B101-30058DA3C1BA Q35467921-040CAFB9-39AB-48F0-AC98-3BD84663CC96 Q35470044-E5156B5F-76C2-4955-8B6A-9CB2CAE153B0 Q35668990-13857308-C979-4EC9-9ED0-CC504738AF31 Q35814369-9FAA5FB3-CA2C-41DD-A8AB-0B37C4F31AAE Q35876403-1AC0BBA2-7337-49CD-A1F0-D9647C974E05 Q36107249-ADDB42C1-DD8E-4046-8EBA-5A41497E2B6A Q36475090-D57AE8E4-B13A-4B7A-A69A-07310BEF7669 Q36544994-5D819B62-EEDD-43C7-BE5A-9D063EC92C27 Q36562190-D353DBA9-39A3-4237-9A4D-E913CAFDE29B Q36859507-8DDEFDAC-75AB-4FF5-B66C-4F98E86C0D68 Q36923575-ECF73A8E-C2B5-481B-B2F9-411513FE847B Q37108146-AC444C42-C16C-417F-97B4-4C864F9E68E5 Q37396299-A1082DA3-A162-43AE-AA92-4F8E71432DF3 Q37464280-A09D0D91-8CF0-4560-9172-A31B55E948B9 Q37704441-5E10A2A7-13BA-4822-B880-E67F14032073 Q37967607-1E44D2F5-2212-40C0-8AB8-1B981E5A0F2F Q38663636-72B071EC-9966-462A-9A12-83267D6946B8 Q40633295-347F63BF-B54F-465B-A27A-5F6CED6A02D1

P2860

Donepezil therapy in clinical practice: a randomized crossover study.

http://www.wikidata.org/entity/Q33145215

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Donepezil therapy in clinical practice: a randomized crossover study.

@ast

Donepezil therapy in clinical practice: a randomized crossover study.

@en

type

label

Donepezil therapy in clinical practice: a randomized crossover study.

@ast

Donepezil therapy in clinical practice: a randomized crossover study.

@en

prefLabel

Donepezil therapy in clinical practice: a randomized crossover study.

@ast

Donepezil therapy in clinical practice: a randomized crossover study.

@en

P1433

Q33145215-AD2427A0-B4D7-41DE-A147-9A0F60DA5E25

P1476

Q33145215-B90622BF-CEB1-48A6-A91F-2421766FCD61

P2093

Q33145215-0B88396C-6E40-4C50-8850-DA8BA9A5449F

Q33145215-1398BC79-E5B5-4D30-B684-092ACA97E74F

Q33145215-1E945E2F-98D3-4FFB-A16D-495ED737AA0A

Q33145215-3C85DAD6-92EB-4606-8C4E-B1AEDBDFAA18

Q33145215-4C7D016F-31F1-49F4-A9D1-466ED4CB2FBB

Q33145215-4DBD7B22-B743-484A-874B-69B6DC7E7702

Q33145215-5F7A6843-E29A-4759-B186-DAB4A6EEC842

Q33145215-72E1B01B-6B14-41CC-82A7-235510A5A465

Q33145215-7FA9AC1F-4A62-4A9D-8F4F-AD6501E846F6

Q33145215-88AAFA11-6455-4870-A953-42A151DF66F8

P304

Q33145215-178A51CB-1ACD-4804-B08C-8538B58E6817

P31

Q33145215-7C278720-A20C-433E-BAED-17A31EBA597E

P356

Q33145215-406D389F-87AD-4380-A797-8938CB75CA42

P433

Q33145215-9E213383-BE23-429A-8642-3DC219EBDF7B

P478

Q33145215-894E3261-7428-42F3-AE78-481A283E53B9

P577

Q33145215-724434FF-79D5-437E-B7F2-2DB210E93D8A

P698

Q33145215-A652465B-66B7-4AC4-9A79-E3CAE2641439

P356

ARCHNEUR.57.1.94

P1433

P1476

Donepezil therapy in clinical practice: a randomized crossover study.

@en

P2093

Brown LB

http://www.w3.org/2001/XMLSchema#string

Corwin C

http://www.w3.org/2001/XMLSchema#string

Daffner KR

http://www.w3.org/2001/XMLSchema#string

Friedman P

http://www.w3.org/2001/XMLSchema#string

Gomez-Isla T

http://www.w3.org/2001/XMLSchema#string

Greenberg SM

http://www.w3.org/2001/XMLSchema#string

Growdon JH

http://www.w3.org/2001/XMLSchema#string

Hayden DL

http://www.w3.org/2001/XMLSchema#string

Meadows ME

http://www.w3.org/2001/XMLSchema#string

Schoenfeld DA

http://www.w3.org/2001/XMLSchema#string

P304

94-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1001/ARCHNEUR.57.1.94

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10634454

http://www.w3.org/2001/XMLSchema#string